Evolving Strategies for the Prevention of Influenza Infection

No abstract is available for this paper.

• Publication year

  2012

• Venue

  BioDrugs

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2165/00063030-200620060-00003PMID 17176120
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prophylaxis and Treatment of Influenza Virus Infection

  2012cited by this paper
• Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature.

  2006cited by this paper
• T Cell Responses Are Better Correlates of Vaccine Protection in the Elderly1

  2006cited by this paper
• Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

  2006cited by this paper
• Influenza Type A Virus Escape Mutants Emerge In Vivo in the Presence of Antibodies to the Ectodomain of Matrix Protein 2

  2005cited by this paper
• Universal influenza A vaccine: optimization of M2-based constructs.

  2005cited by this paper
• Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor

  2005cited by this paper
• Influenza: lessons from past pandemics, warnings from current incidents

  2005cited by this paper
• Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design.

  2005cited by this paper
• Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

  2004cited by this paper
• A "universal" human influenza A vaccine.

  2004cited by this paper
• High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity.

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.

  2004cited by this paper
• Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome.

  2004cited by this paper
• Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly1

  2004cited by this paper
• Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands

  2004cited by this paper
• Mapping the Antigenic and Genetic Evolution of Influenza Virus

  2004cited by this paper
• Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

  2003cited by this paper
• Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

  2003cited by this paper
• Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

  2002cited by this paper
• Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

  2002cited by this paper
• Directed Egress of Animal Viruses Promotes Cell-to-Cell Spread

  2002cited by this paper
• Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

  2001cited by this paper
• Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

  2001cited by this paper
• Characterization of the pathogenicity of members of the newly established H9N2 influenza virus lineages in Asia.

  2000cited by this paper
• Global epidemiology of influenza: past and present.

  2000cited by this paper
• Profound Protection against Respiratory Challenge with a Lethal H7N7 Influenza A Virus by Increasing the Magnitude of CD8+ T-Cell Memory

  2000cited by this paper
• Heterologous protection against lethal A/HongKong/156/97 (H5N1) influenza virus infection in C57BL/6 mice.

  2000cited by this paper
• DNA immunization: mechanistic studies.

  1999cited by this paper
• Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.

  1999cited by this paper
• Modified M2 proteins produce heterotypic immunity against influenza A virus.

  1999cited by this paper
• Human infection with influenza H9N2.

  1999cited by this paper
• A universal influenza A vaccine based on the extracellular domain of the M2 protein

  1999cited by this paper
• Contribution of  Virus-specific CD8+ Cytotoxic T Cells to Virus Clearance or Pathologic Manifestations of Influenza Virus Infection in a T Cell Receptor Transgenic Mouse Model

  1998cited by this paper
• A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection.

  1998cited by this paper
• Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness.

  1998cited by this paper
• Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA

  1998cited by this paper
• avian influenza virus

  1997cited by this paper
• Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.

  1995cited by this paper
• Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly.

  1995cited by this paper
• Heterologous protection against influenza by injection of DNA encoding a viral protein.

  1993cited by this paper
• Transgenic mice lacking class I major histocompatibility complex- restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge

  1992cited by this paper
• Structural characteristics of the M2 protein of influenza a viruses: Evidence that it forms a tetrameric channe

  1991cited by this paper
• Amantadine selection of a mutant influenza virus containing an acid-stable hemagglutinin glycoprotein: evidence for virus-specific regulation of the pH of glycoprotein transport vesicles.

  1991cited by this paper
• Cross-reactive protection against influenza A virus infections by an NS1-specific CTL clone.

  1990cited by this paper
• Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice

  1990cited by this paper
• Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells.

  1989cited by this paper
• Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

  1988cited by this paper
• Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo.

  1986cited by this paper
• Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses.

  1985cited by this paper
• Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.

  1985cited by this paper
• Cytotoxic T-cell immunity to influenza.

  1983cited by this paper

• IMMUNE RESPONSES TO MICROBES

  2020cites this paper
• Inactivated and adjuvanted influenza vaccines.

  2015cites this paper
• Augmentation de l'immunogénicité de la nucléoprotéine de l'influenza par multimérisation in vitro

  2015cites this paper
• Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter

  2014cites this paper
• Vaccine Technologies & the Rationale for New Nanoparticle Formulations

  2014cites this paper
• Study of immunogenicity of recombinant proteins based on hemagglutinin and neuraminidase conservative epitopes of Influenza A virus

  2013cites this paper
• Immunobiology of influenza vaccines.

  2013cites this paper
• Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza a virus in mice

  2013cites this paper
• Characterization of Influenza H5N1 Nucleocapsid Protein for Potential Vaccine Design

  2012cites this paper
• Return of inactivated whole‐virus vaccine for superior efficacy

  2012cites this paper
• Robust Immunity and Heterologous Protection against Influenza in Mice Elicited by a Novel Recombinant NP-M2e Fusion Protein Expressed in E. coli

  2012cites this paper
• Tailored influenza virus vaccines for both the young and old: Vaccine Efficacy of Whole Inactivated Vaccines bearing Immunomodulatory Adjuvants or Multimeric peptides

  2012cites this paper
• Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience.

  2011cites this paper
• Oral and Poster Manuscripts

  2011cites this paper
• Aviäre Influenzavirus (AIV) Markervakzinen auf Basis des Newcastle Disease Virus (NDV) als Vektor

  2010cites this paper
• Influenza control in the 21st century: Optimizing protection of older adults.

  2009cites this paper
• Influenza vaccines and vaccination strategies in birds.

  2008cites this paper
• Emerging vaccines for influenza

  2008cites this paper
• Structure of the influenza virus A H5N1 nucleoprotein: implications for RNA binding, oligomerization, and vaccine design

  2008cites this paper
• Influenza vaccine: the challenge of antigenic drift.

  2007cites this paper